Skip directly to content


Inlyta® is a second line oral therapy that targets VEGF receptor-related renal cell abnormalities1. Inlyta® has been enlisted as subsidized medical treatment against one specific disease by the Community Care Fund2.



  1. Inlyta® (axitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version August 2014
  2. Safety Net. HA Drug Formulary Management.  Accessed on 8 August 2019.
[PP-CPF-HKG-0070] SEP 2019

Therapeutic Area Sub Category: